Life Sciences

Tim works with Cambridge University Hospitals (CUH) Department of Research and Development and Cambridge Enterprise to identify and commercialise intellectual property originating from research carried out within the NIHR Cambridge Biomedical Research Centre, a partnership between Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge.

He works closely with academics and clinicians to build business opportunities, paving the route to market and securing translational grant funding and other activities to ultimately license or spin-out the technology opportunity.

After an early career in scientific publishing at Cambridge University Press and the Royal Society of Chemistry, Tim joined UCL Business (UCLB), UCL’s technology transfer company.  Working primarily with academics from the Physical Science and Engineering faculties and the London Centre for Nanotechnology he led on the protection of new IP, helped secure proof-of-concept funding and managed commercialisation activities.  He transacted numerous patent and know-how licences and led on the creation of two spin-outs including a company developing a microencapsulation technology for production of multi-layered drug capsules. Tim also co-led the early development of E-Lucid, an online licensing platform for the management of contracts for low-cost, high-volume IP assets, which is now in use across the sector.

After UCLB, Tim moved into the NHS.   As Head of Technology Transfer at Health Enterprise East (now HeathTech Enterprise) he worked closely with clinical innovators from NHS Trusts across the Eastern region and London.  He helped secure significant translational grants from funders such as the NIHR and the MedtechAccelerator and licensed a number of novel medical devices on behalf of host NHS Trusts.

More recently Tim was Head of Professional Development and Membership at PraxisAuril, the UK’s professional association for Knowledge Exchange.  Here he managed the training portfolio helping to develop, upskill and network the UK’s knowledge exchange and technology transfer community.

Tim has a BA in Chemistry and D.Phil. in Materials Science from Oxford University.

Tim joined Cambridge Enterprise in January 2024

Anna Davies is an Academic Relations Manager for Life Sciences. She is focused on growing relationships with researchers working in the life sciences and developing impact through commercialisation.

Before joining Cambridge Enterprise, Anna worked at the University of Cambridge in a variety of roles, co-ordinating a cross-University interdisciplinary network of infectious disease researchers, facilitating research strategy and impact at the Department of Veterinary Medicine. Through a secondment, she also worked closely with academics from across the life sciences to deliver impact case studies for the 2021 Research Excellence Framework (REF) exercise. She joined Cambridge after several years working at the public health laboratories in Porton Down, where she undertook research on aerosol disease transmission and biosafety.

Anna has a degree in Microbiology from the University of Warwick.

Anna joined Cambridge Enterprise in February 2023.

Ed is a Business Development Manager and is responsible for increasing revenue generation from technology licenses.

Prior to joining Cambridge Enterprise, Ed worked for a multinational wood pulp company, specialising in biorefinery technology and leading R&D teams in the UK, the Netherlands and Austria, with scale up piloting in both North America and South Africa. The underpinning science for these projects was originally developed in a start-up company that Ed co-founded to commercialise some of his academic research from Imperial College London.

From 2005-2010 Ed was a lecturer in Green Chemistry at Imperial and he holds a PhD in Polymer Chemistry from Durham University. He has co-authored >60 academic papers and patents.

Ed joined Cambridge Enterprise in November 2022.

PA (Job share with Zoe Prior) to Dr Iain Thomas, Interim Head of Technology Transfer and The Technology Transfer Team.

Prior to joining Cambridge Enterprise she spent 2 ½ years working for the Local Authority in Children’s Services, and has a range of administrative experience working in both healthcare and retail sectors.

Anna joined Cambridge Enterprise in July 2022.

Oleksandra is a Senior Commercialisation Associate in the Physical Sciences team.

Prior to joining Cambridge Enterprise Oleksandra worked as a scientist in Corporate Venturing team at Cambridge Display Technology (CDT) Ltd where she was looking for start-up companies to partner with for CDT’s parent company Sumitomo Chemical. She also worked as a chemist in Organic Photodiode team, designing and synthesising new photoactive materials.

Oleksandra holds a PhD in chemistry/photophysics from the University of Sheffield. She also has BSc in Chemistry from Taras Shevchenko National University of Kyiv (Ukraine) and MSc in Applied Chemistry from Kaunas University of Technology (Lithuania).

Oleksandra joined Cambridge Enterprise in August 2022.

Emma is a Senior Commercialisation Associate in the Life Sciences team, providing support for the evaluation of new technologies, protection of intellectual property and developing commercial opportunities arising from University research.

Prior to joining Cambridge Enterprise, Emma spent more than two years as a trainee patent attorney at a top tier UK patent law firm. She previously completed a PhD and short post-doctoral research position in Plant Genetics at the University of Cambridge. She also has a BA in Biological Natural Sciences from the University of Cambridge.

She is an author on five academic publications and is a part-qualified UK and European patent attorney.

Emma joined Cambridge Enterprise in March 2022.

Adam is a Commercialisation Manager in the Physical Sciences Team where he works to commercialise technologies from across the physical sciences.

Prior to joining Cambridge Enterprise, Adam spent approximately fifteen years working in industrial and academic research and innovation settings. He previously worked as Head of Research Programme and CIH Programme Lead for the Centre for Digital Built Britain, funding and managing innovative research as a partner organisation in the £72m Innovate UK-funded Construction Innovation Hub. His work contributed to UKRI’s Transforming Construction Challenge, ensuring industrial impact from academic research, aiming to transform the construction industry via innovative digital tools and ways of working.

Prior to this he was Senior Specialist at Beko, where he was involved in setting up and running parent company Arçelik’s first international R&D centre in Cambridge, developing technologies and new products in collaboration with academic partners and start-ups. He previously worked at Nokia, where he was responsible for developing inventions for Nokia’s next-generation devices. This followed a period of academic post-doctoral research at Cambridge University across a range of topics including novel nanostructures, solar cells, superconductivity, flexible electronic devices and bioimplants, and insect biomechanics.

Adam is trained as a physicist with an MPhys from Lancaster University, a PhD in experimental physics from the University of Bristol, and is a Chartered Physicist.

Adam joined the Cambridge Enterprise team in July 2020.

Zoe shares the role of PA to the Technology Transfer team with Anna Waldock.

Zoe has experience in supporting and leading teams and before joining Cambridge Enterprise was PA to the CEO and Office Manager at software company, IPV. Prior to this, her roles included Team Leader within the HR Department at Anglian Water and People Team Coordinator at Redgate Software.

Zoe holds an ISEB Programme and Project Management qualification.

Zoe joined Cambridge Enterprise in October 2019.

Terry is responsible for the commercialisation and diffusion of Life Science and health-related technologies and research arising from the University of Cambridge through the creation of new companies, licensing relationships and partnerships.

In the past year, Terry has been responsible for the commercialisation of several Cambridge technologies, including the licensing of stem cell products and cancer risk prediction tools and the development of investment opportunities in the fields of Flu and Ebola vaccines and a number of opportunities related to cell therapy.

Terry was previously the Head of Intellectual Property and Commercial Research at Guy’s and St Thomas’ Hospital for over 10 years, having founded and grown a technology transfer department that commercialised NHS inventions from ‘bedside to business’. There he commercialised a variety of technologies including medical devices, software, imaging technologies, laboratory products, novel formulations, in vitro diagnostics and service based IP. He has also been involved in the creation of novel partnerships for the National Health Service such as Viapath (a £500m pathology joint venture with Serco) and Essentia Trading Ltd (a facilities spin-out company). In addition, Terry supported the formation of technology-based spin-out companies including Cydar and SpOtOn Clinical Diagnostics amongst others and has served as a Director for several spin-out companies. Terry was also responsible for founding a Proof of Concept investment fund and setting up a commercial research and consultancy service within the NHS to interface with industry. Prior to this, Terry was Acting Director of MediChIP, the NHS Innovation Hub for SE/SW London. He then became part of the change management team responsible for the merger of the London NHS Innovation hubs to form a single tech-transfer unit (NHS Innovations London).

Terry has a PhD in immunology and gene silencing and held a postdoctoral research position within the UK’s first stem cell spin-out company, Cerestem Ltd.

Terry joined Cambridge in February 2018.

Phil is Commercialisation Director in the Technology Transfer Team where he works to commercialise technologies from across the life sciences, with a particular interest in new medicines.

University of Cambridge spin out company PolyProx Therapeutics was established in 2019 with Phil’s support, raising £3.4m seed financing.

Prior to joining Cambridge Enterprise, Phil spent 17 years at Cancer Research Technology (CRT), the commercialisation arm of the charity Cancer Research UK, ultimately as Head of Commercial Portfolio. During his time at CRT, Phil established a strategic partnership with Newcastle University, and worked part-time across both organisations in a technology transfer role. Notably he led the formation of Newcastle University’s five-year cancer drug discovery alliance with Astex Pharmaceuticals, initiated Newcastle’s $31m part-monetization of its royalty interest in cancer drug Rubraca, and was CEO of Demuris Limited, a University spin-out company focussed on antibiotic drug discovery.

Phil has a PhD in developmental biology from the MRC’s National Institute for Medical Research (now the Francis Crick Institute).

With an interest in training and coaching, Phil has been a member of PraxisAuril’s Professional Development Committee since May 2013 and helps to design and deliver courses on technology transfer and strategic partnerships.

Phil joined the Cambridge Enterprise team in March 2018.

Jennie works closely with others in both the Physical and Life Sciences teams to support commercialisation of research outputs primarily from the School of Physical Sciences and the School of Technology in the University of Cambridge.

With a focus on creating positive societal impact, Jennie is proactive in assessing technology with the most potential to be disruptive, and then working closely with our academic and internal stakeholders to find the best routes to market.

Prior to joining Cambridge Enterprise, Jennie worked as a Product Specialist for a major biotechnology company, with an emphasis on global regulatory compliance.

Jennie has a Masters degree in Chemistry from the University of Sussex and a PhD in Chemistry from the University of Cambridge. Jennie’s Master’s research focused on quantum dot synthesis for single molecule fluorescence applications for her Masters. This led her to study the aggregation of amyloid beta 42 (a peptide implicated in Alzheimer’s Disease) using single molecule fluorescence techniques and microfluidics during her PhD.

Jennie joined Cambridge Enterprise in August 2016.

Helen works across the Life Sciences Team, providing support for the evaluation, IP protection and licensing of technologies arising from the Schools of Biological Sciences and Clinical Medicine.

Recent support has been for the licensing of technologies to Phoremost, Storm Therapeutics and PredictImmune.

Prior to joining Cambridge Enterprise, Helen spent 15 years working for various SME’s in the biotech sector within the Cambridge region, where she held positions in process development and formulation for vaccines and biotherapeutics.

Helen has a PhD in Mucosal Glycobiology from the University of Manchester.

Helen joined Cambridge Enterprise in October 2013.